The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 58, Issue 3, 1999, Pages 193-195

  Reward, Joanne ^a   Gordon, Caroline ^b   Allahabadia, Amit ^c   Barnett, Anthony H ^a   Franklyn, Jayne A ^b   Gough, Stephen C L ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANTIGEN PRESENTING CELL; ARTICLE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; EXON; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032941712     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.3.193     Document Type: Article

References (15)

1. Hochberg MC. The application of genetic epidemiology to systemic lupus erythematosus. J Rheumatol 1987; 14:867-9.
2. Kaplan D. The onset of disease in twins and siblings with systemic lupus erythematosus. J Rheumatol 1984;! 1:648-52.
3. Deapen DM, Escalante A, Yi'einrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of win concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311-18.
4. Hamilton RG, Harley JB, Bias \VB, Roebber M, Reichlin M, Hochberg MC, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus: correlation of HLA DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496-505.
5. Jarjour W, Reed AM, Gauthier J, Hunt S, Winfield JB. The 8.5-kb Pst I allele of the stress protein gene, Hsp 70-2. An independent risk factor for systemic lupus erythematosus in African Americans. Hum Immunol 1996;45:59-63.
6. \Vilson AG, Gordon C, di Giovine FS, de Vries N, van de Putte LB, Emery P, et al. A genetic association between systemic lupus erythematosus and tumour necrosis factor alpha. EurJ Immunol 1994;24:191-5.
7. Steinberg AD, Gourlet MF, Klinman DM, Tsokos GC, Scott DE, Krieg AM. Systemic lupus erythematosus. Ann Intern Med 1991;115:548-59.
8. \\"ofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZ\V Fl mice with monoclonal antibody to L3T4.JExpMed 1985;161:378-91.
9. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997;128:1989-93.
10. Finck BK, Linsley PS, \Vofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
11. Donner H, Rau H, \VaIfish PG, Braun J, Siegmund T, Finke R, et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type I diabetes mellitus. J Clin Endocrinol Metab 1997;82:143-6.
12. Tan EG, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Dariavich P, Mattéi M-G, Golstein P, Lefranc M-P. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein seqeunce between murine and human CTLA-4 cytoplsmic domains. Eur J Immunol 1988;18:190I-5.
14. Hathcock KS, Laszlo G, Dickler HE, Bradshaw J, Linsley P, Modes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993;262: 905-7.
15. Mehrian R, Quismorio FP, Strassmann G, Stimmler MM, Honvitz DA, Kitridou RC, et al. Synergistic effect between IL-10 and bcl-2 genorjpes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41: 596-602.